Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice
Crossref DOI link: https://doi.org/10.1007/s10147-014-0727-x
Published Online: 2014-07-11
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gavilá, Joaquín
Guerrero, Ángel
Climent, Miguel Ángel
Fernández, Aranzazu
Gozalbo, Francisco
Carrascosa, María
Camps, Josefina
Guillem, Vicente
Ruiz, Amparo
Text and Data Mining valid from 2014-07-11